Literature DB >> 27532215

Bifidobacterium longum Subspecies infantis Bacteremia in 3 Extremely Preterm Infants Receiving Probiotics.

Eirin Esaiassen, Pauline Cavanagh, Erik Hjerde, Gunnar S Simonsen, Ragnhild Støen, Claus Klingenberg.   

Abstract

Entities:  

Keywords:  Bifidobacterium longum subspecies infantis; Infloran; Norway; bacteremia; bacteria; oral probiotics; preterm infants; probiotic supplementation; probiotics

Mesh:

Year:  2016        PMID: 27532215      PMCID: PMC4994345          DOI: 10.3201/eid2209.160033

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Metaanalysis of randomized trials that tested different probiotics showed a reduction of ≈50% in necrotizing enterocolitis and all-cause deaths in preterm infants (). Use of probiotics is increasing worldwide (,), and cases of probiotic sepsis were not reported among >5,000 infants in an updated review (). In Norway, a consensus-based protocol recommending prophylactic probiotic supplementation for preterm infants at highest risk for necrotizing enterocolitis (gestational age <28 weeks, birthweight <1,000 g) was introduced in 2014. After considering the safety profile, we investigated use in preterm infants of a widely used combination of oral probiotics (Infloran; Laboratorio Farmacéutico Specialità Igienico Terapeutiche, Mede, Italy) that contained 109 Lactobacillus acidophilus (ATCC 4356) and 109 Bifidobacterium longum subspecies infantis (ATCC 15697). B. longum is a microaerotolerant, anaerobic bacterium susceptible to many antimicrobial drugs (Table). This bacterium is a rare cause of neonatal infections; until 2015, only 2 Bifidobacterium bacteremia cases in premature newborns had been reported (,).
Table

Characteristics of 3 extremely preterm infants with Bifidobacterium longum subspecies infantis bacteremia, 2015*

CharacteristicPatient 1Patient 2Patient 3
NICUABA
SexMMF
Date of onsetAprJulSep
Gestational age, wk242324
Birth weight, g730500697
Mode of deliveryVaginalVaginalCaesarean section
Apgar score at 1, 5, and 10 min after birth4, 5, 5Unknown, 0, 42, 2, 3
Reason for prematurityPreterm rupture of membranes, maternal infectionSudden preterm rupture of membranes, delivery not attended by healthcare personnelPlacental abruption
Age at onset of sepsis, d81246
Maximum CRP level, mg/L, <48 h of symptom onset14725242
Age at discharge, wk404143
Weight at discharge, kg3.33.43.3
Bacterial culture medium and conditionsBacT/ALERT,† aerobic, 36°CBACTEC Plus,† aerobic, 35°CBacT/ALERT,† aerobic, 36°C
Bacterial growth in blood culture, d232

*Patients were given ½ to 1 capsule/day of oral probiotics (Infloran; Laboratorio Farmacéutico Specialità Igienico Terapeutiche, Mede, Italy) that contained 109 Lactobacillus acidophilus (ATCC 4356) and 109 B. longum subspecies infantis (ATCC 15697). MICs (mg/L) for antimicrobial drugs tested were 0.016 for meropenem, 0.032 for ampicillin, 0.064 for penicillin, 0.064 for piperacillin/tazobactam, 0.250 for cefotaxime, 0.250 for clindamycin, 0.250 for vancomycin, and 4.000 for ciprofloxacin. All bacterial strains were inherently resistant to aminoglycosides. ATCC, American Type Culture Collection (Manassas, VA, USA); CRP, C-reactive protein; NICU, neonatal intensive care unit.
†bioMérieux (Marcy l’Étoile, France).

*Patients were given ½ to 1 capsule/day of oral probiotics (Infloran; Laboratorio Farmacéutico Specialità Igienico Terapeutiche, Mede, Italy) that contained 109 Lactobacillus acidophilus (ATCC 4356) and 109 B. longum subspecies infantis (ATCC 15697). MICs (mg/L) for antimicrobial drugs tested were 0.016 for meropenem, 0.032 for ampicillin, 0.064 for penicillin, 0.064 for piperacillin/tazobactam, 0.250 for cefotaxime, 0.250 for clindamycin, 0.250 for vancomycin, and 4.000 for ciprofloxacin. All bacterial strains were inherently resistant to aminoglycosides. ATCC, American Type Culture Collection (Manassas, VA, USA); CRP, C-reactive protein; NICU, neonatal intensive care unit.
†bioMérieux (Marcy l’Étoile, France). A total of 290 extremely preterm infants received oral probiotics during April 2014–August 2015 in Norway. Three patients were given a diagnosis of B. longum bacteremia: 2 patients in a neonatal unit in which 17 patients were given oral probiotics and 1 patient in a neonatal unit in which 31 patients were given oral probiotics (Table). All 3 infants had respiratory distress syndrome and received mechanical ventilation after birth. Enteral feeding with human milk was begun on day 1. Oral probiotics (½ capsule, 1×/d) were given during the first week of life and increased to 1 capsule/day after 4–7 days. We identified B. longum in blood cultures by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, Billerica, MA, USA). Whole-genome sequencing (MiSeq, Illumina, San Diego, CA, USA) and comparative analysis of nucleotide-level variation by using variant cell format in SAMtools (http://samtools.sourceforge.net) showed that all 3 blood culture isolates and a B. longum strain cultured from an oral probiotic capsule were identical. Patient 1 had sepsis and severe hypotension 8 days after birth. A blood culture was prepared, and the patient was given antimicrobial drugs and vasoactive support. Abdominal distention, gastric residuals, and feed intolerance developed the next day, but the patient was cardiorespiratory stable. On day 12, abdominal radiographs showed pneumoperitoneum. Surgery showed multiple ileal perforations and bowel necrosis. Histologic analysis showed classical features of necrotizing enterocolitis. The patient received an ileostoma and improved after treatment with antimicrobial drugs. Blood culture was positive for gram-positive rods, which were identified as B. longum. Subsequent clinical course was uneventful. Patient 2 had apnea, bradycardia, and temperature instability 12 days after birth. A blood culture was prepared, and the patient was given antimicrobial drugs. Blood culture was positive for gram-positive rods, which were identified as B. longum. Use of oral probiotics was discontinued. The patient recovered rapidly, and subsequent clinical course was uneventful. Patient 3 had sepsis and necrotizing enterocolitis 9 days after birth. Ultrasound showed free abdominal fluid. A blood culture was prepared, and the patient was given antimicrobial drugs. Surgery showed 2 separate bowel perforations, and the patient received an ileostoma and colostoma. Histologic analysis did not show necrosis or inflammation. Enterococcus faecalis grew in the blood culture obtained on day 9. The patient had a complicated clinical course and received prolonged mechanical ventilation. However, the patient gradually tolerated full feeds. Use of oral probiotics was continued. On day 46, the condition of patient 3 suddenly deteriorated; hypotension and metabolic acidosis developed, and the patient was again given antimicrobial drugs. A blood culture was positive for B. longum. Supplementation with oral probiotics was discontinued. The patient recovered from the infection, but secondary ileus developed. The patient had a complicated clinical course until discharge. Recently, 5 other B. longum bacteremia cases among 5 preterm infants at 26–31 weeks gestation were reported (,). All 5 infants had received oral probiotics; 3 had severe gastrointestinal complications, similar to patient 1 in our report, and 2 patients were moderately compromised, similar to patient 2 (,). We do not know whether Bifidobacterium organisms in blood culture for patient 1 were a consequence of intestinal necrosis and bacterial translocation or the cause of necrotizing enterocolitis. Patient 3 probably had a leaky gut that predisposed this patient to bacterial translocation. All 3 patients were extremely premature (23–24 weeks gestation) and had impaired immune systems, which predisposed them to infections with bacteria with low virulence. A recently published case of Bifidobacterium bacteremia in a 2-year old boy with leukemia highlights impaired immunity as a risk factor (). Only aerobic blood cultures are prepared for neonates. We detected Bifidobacterium bacteremia by using 2 automated blood culture systems and aerobic bottles. However, the sensitivity of these systems for detecting Bifidobacterium bacteremia is unknown. Thus, the incidence of Bifidobacterium bacteremia is theoretically underestimated. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry improves species detection and its use might be 1 reason for the apparently recent increase in probiotic-associated bacteremia. We report that systemic infection with probiotic bacteremia might have a severe clinical course in extremely preterm infants. Clinical suspicion and appropriate blood culture conditions are essential for proper diagnosis and management.
  8 in total

1.  Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy.

Authors:  Andreas Jenke; Eva-Maria Ruf; Thomas Hoppe; Michael Heldmann; Stefan Wirth
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2011-11-04       Impact factor: 5.747

2.  Cohort study of probiotics in a North American neonatal intensive care unit.

Authors:  Annie Janvier; Josianne Malo; Keith J Barrington
Journal:  J Pediatr       Date:  2014-01-07       Impact factor: 4.406

3.  Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy.

Authors:  Andrea Zbinden; Reinhard Zbinden; Christoph Berger; Romaine Arlettaz
Journal:  Neonatology       Date:  2014-11-07       Impact factor: 4.035

4.  Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele.

Authors:  Akira Ohishi; Shigehiro Takahashi; Yushi Ito; Yoshihisa Ohishi; Keiko Tsukamoto; Yukiko Nanba; Naoki Ito; Satsuki Kakiuchi; Akihiko Saitoh; Masami Morotomi; Tomoo Nakamura
Journal:  J Pediatr       Date:  2010-04       Impact factor: 4.406

5.  Bifidobacterium longum bacteremia in preterm infants receiving probiotics.

Authors:  Claire Bertelli; Trestan Pillonel; Anaïs Torregrossa; Guy Prod'hom; Céline Julie Fischer; Gilbert Greub; Eric Giannoni
Journal:  Clin Infect Dis       Date:  2014-12-03       Impact factor: 9.079

Review 6.  Probiotics for prevention of necrotizing enterocolitis in preterm infants.

Authors:  Khalid AlFaleh; Jasim Anabrees
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

7.  Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis probiotics and outcome in very low birth weight infants.

Authors:  Christoph Härtel; Julia Pagel; Jan Rupp; Meike Bendiks; Florian Guthmann; Esther Rieger-Fackeldey; Matthias Heckmann; Axel Franz; Jan-Holger Schiffmann; Beate Zimmermann; Nico Hepping; Axel von der Wense; Christian Wieg; Egbert Herting; Wolfgang Göpel
Journal:  J Pediatr       Date:  2014-05-29       Impact factor: 4.406

8.  Bifidobacterium breve Sepsis in Child with High-Risk Acute Lymphoblastic Leukemia.

Authors:  Simona Lucija Avcin; Marko Pokorn; Lidija Kitanovski; Manica Mueller Premru; Janez Jazbec
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

  8 in total
  23 in total

Review 1.  To start or not: Factors to consider when implementing routine probiotic use in the NICU.

Authors:  Maria E Barbian; Rachel Buckle; Patricia Wei Denning; Ravi Mangal Patel
Journal:  Early Hum Dev       Date:  2019-06-10       Impact factor: 2.079

2.  Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity.

Authors:  Eirin Esaiassen; Erik Hjerde; Jorunn Pauline Cavanagh; Gunnar Skov Simonsen; Claus Klingenberg
Journal:  J Clin Microbiol       Date:  2017-05-10       Impact factor: 5.948

3.  [Clinical guidelines for the diagnosis and treatment of neonatal necrotizing enterocolitis (2020)].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-01

Review 4.  Probiotic supplementation for neonates with congenital gastrointestinal surgical conditions: guidelines for future research.

Authors:  Shripada Rao; Meera Esvaran; Liwei Chen; Chooi Kok; Anthony D Keil; Ian Gollow; Karen Simmer; Bernd Wemheuer; Patricia Conway; Sanjay Patole
Journal:  Pediatr Res       Date:  2022-05-03       Impact factor: 3.756

Review 5.  Probiotic sepsis in preterm neonates-a systematic review.

Authors:  Tithi Kulkarni; Swati Majarikar; Mangesh Deshmukh; Anitha Ananthan; Haribalakrishna Balasubramanian; Anthony Keil; Sanjay Patole
Journal:  Eur J Pediatr       Date:  2022-03-29       Impact factor: 3.183

Review 6.  Synbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants.

Authors:  Sahar Sharif; Paul T Heath; Sam J Oddie; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2022-03-01

7.  Safety and efficacy of probiotic administration to preterm infants: ten common questions.

Authors:  Mark A Underwood; Erin Umberger; Ravi M Patel
Journal:  Pediatr Res       Date:  2020-08       Impact factor: 3.756

8.  Bifidobacterium: An Emerging Clinically Significant Metronidazole-resistant Anaerobe of Mixed Pyogenic Infections.

Authors:  Hena Butta; Raman Sardana; Raju Vaishya; Kailash N Singh; Leena Mendiratta
Journal:  Cureus       Date:  2017-04-04

Review 9.  Probiotics' efficacy in paediatric diseases: which is the evidence? A critical review on behalf of the Italian Society of Pediatrics.

Authors:  Massimo Martinelli; Giuseppe Banderali; Marisa Bobbio; Elisa Civardi; Alberto Chiara; Sofia D'Elios; Andrea Lo Vecchio; Mattia Olivero; Diego Peroni; Claudio Romano; Mauro Stronati; Renato Turra; Irene Viola; Annamaria Staiano; Alberto Villani
Journal:  Ital J Pediatr       Date:  2020-07-25       Impact factor: 2.638

10.  Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants.

Authors:  Sahar Sharif; Nicholas Meader; Sam J Oddie; Maria Ximena Rojas-Reyes; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.